Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis.

Abstract: A new class of polymers based upon the radialene group as the parent repeating group and characterized by the following general formula: where R1, R2, R3, R4 are each independently any pi electron conjugated group, but not limited to: pyrrole, thiophene, benzene, naphthalene, furan, ethene, aniline, and n is an integer from 2 to 20,000. Furthermore, the individual R groups can be further functionalized with an alky group having 1 to 22 carbons; alkoxy group having 1 to 22 carbons; alkyl sulfonate having 1 to 22 carbons; alkyl phosphate group containing 1 to 22 carbons, alkoxy phosphate group having 1 to 22 carbons; ethenylendioxy group; propylene dioxy group.

Abstract: A compound for detecting an analyte using Surface Enhanced Raman Spectroscopy (SERS) and a method of forming the compound is provided. The compound has Formula I: wherein W is selected from the group consisting of an optionally substituted aryl group and an optionally substituted heteroaryl group; each Y independently is NR1R2, wherein R1 and R2 are independently selected from the group consisting of H and C1-C6 alkyl, or R1 and R2 combine to form together with the nitrogen to which they are attached a heterocyclic group with 4 to 5 carbon atoms, is used to denote a single or a double bond, and Z is NH, NH2, NH—(C?O)—(CH2)n—SH, wherein n=1 to 10, or or a tautomer or stereoisomer thereof, or a salt thereof. A method and device for detecting an analyte using Surface Enhanced Raman Spectroscopy (SERS) is also provided.

Abstract: The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative.

Abstract: The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (la) or compositions comprising compounds of Structural Formulas (I) and (la), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed.

Abstract: The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.

Abstract: Dithiolane compounds having the structural formula (I): are useful for reinforcing and/or preserving the natural antioxidant protection of the skin against oxidative stress caused, especially, by UV radiation, e.g., by increasing the level of intracellular glutathione.

Abstract: The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug is targeted to and activated by an enzyme of mitochondrial fatty acid beta-oxidation.

Abstract: A stimuli responsive compound includes: a unit A having bonds that function as rotation axes; a first unit B disposed at a first bonding section of the unit A; a second unit B disposed at a second bonding section of the unit A; a first unit C disposed at a third bonding section of the unit A; and a second unit C disposed at a fourth bonding section of the unit A. The first unit B bonds with the second unit B by oxidation-reduction reaction, and the first unit C and the second unit C have liquid crystallinity and include polymerizable functional groups.

Abstract: Fused thiophene (FT) compounds, FT polymers, FT containing articles, and methods for making and using the FT compounds and polymers thereof of the formulas, as defined herein.

Abstract: The present invention relates to compounds of formula (I) with the substituents as defined herein, and uses thereof.

Abstract: A novel spiroquinone derivative having a high ABCA1 stabilization effect and being useful for prophylactic and/or therapeutic agents for various diseases developing hypo-high density lipoproteinemia is obtained. The novel spiroquinone derivative is a compound represented by the following formula: wherein R1a, R1b, R1c and R1d each represents a hydrogen atom, a halogen atom, an alkyl group which may have a substituent, or an alkoxy group which may have a substituent, and R2a and R2b each represents a hydrogen atom, or an alkyl group which may have a substituent (e.g.

Abstract: Ferroelectric liquid crystal compositions including organic ion pair compounds wherein image sticking is reduced or eliminated. Use of the ferroelectric liquid crystal compositions in a ferroelectric liquid crystal display device allows for rapid image refresh rates without required a DC-balancing algorithm. The organic ion pair compounds provide electrical resistivity values for the compositions that result in reduced image sticking when the compositions are used in FLC display devices.

Abstract: A radically polymerizable compound having a group represented by formula (1) (In the formula, R1 to R3 each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, X represents an alkylene group having 1 to 4 carbon atoms.) and a radically polymerizable double bond and a composition for an optical material comprising the same have a high refractive index and excellent transparency and are hard to be oxidized in thermal curing and useful as an optical material with little tinting.

Abstract: Fused thiophene (FT) compounds, FT polymers, FT containing articles, and methods for making and using the FT compounds and polymers thereof of the formulas, as defined herein.

Abstract: Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.

Abstract: A piezoelectric crystal element and a sensor utilizing the same are presented for use in a sensor device for identifying at least one foreign material from environment. The crystal element comprises at least one crystal resonator in the form of a inverted mesa structure, which has a membrane-like region and has a certain resonance frequency value. A surface region of the crystal resonator is modified by reactive molecules of a kind capable of interacting with the foreign material to yield a reaction product that effects a change in the resonance frequency of the crystal resonator from said certain resonance frequency value. This change is indicative of the identity and quantity of the foreign material.

Abstract: This disclosure relates to a polymer containing a first comonomer repeat unit and a second comonomer repeat unit. The first comonomer repeat unit includes a cyclopentadithiophene moiety. The second comonomer repeat unit includes a thienothiophene moiety, a thienothiophene tetraoxide moiety, a dithienothiophene moiety, a dithienothiophene dioxide moiety, a dithienothiophene tetraoxide moiety, or a tetrahydroisoindole moiety. The polymer can be used as a photoactive material in a photovoltaic cell. This disclosure also relates to such photovoltaic cells, as well as modules containing such photovoltaic cells.

Abstract: An organic semiconductor material represented by the following general formula (1): wherein X1 to X4 each independently represent a chalcogen atom; and at least one of R1 and R2 represents a substituent for obtaining solubility, and R1 and R2 may be connected to each other to form a ring.

Abstract: Spirotetrathiocarbamates (STOCs) or oxa substituted compounds (SOTOCs) of Formula I: Formula (I) or bisSTOC or bisSOTOC compounds of Formula II: Formula (II) wherein X1, X2, X3, X4, X5, X6, X7, and X8, are independently O or S; and preferably at least two and up to all four of X1, X2, X3 and X4, and at least two and up to all four of X5, X6, X7, and X8 are sulfur; Z is —CmR22m wherein m=1 to 4; —C(R2)2SC(R2)2—, C(R2)2SSC(R2)2—, or —C(R2)OC(R2)2; n is from 0 to 4; M is selected from CH2Cl, CH2SC(O)R1, CH2SC(S)R1, CH2S(CH2CH2S)qH wherein q is 0, 1 or 2; —CR2?CH2, —CH2OC(O)CR2?CH2, CH2N?C?S, CH2N?C?O, CH2NR2H, CH2OH, CH2SCH2CH2CR2?CH2, phenyl, C(R2)phenyl, furan, thiophene, halogen, C3-C6 cycloalkyl, C3-C6 heretocyclics, thiol, H, (III) or (IV) wherein A is S, O or phenyl; x is 0 or 1; R1 is C1-C22 alkyl; and R2 is H or C1-C22 alkyl have excellent optical properties. Methods for preparing these compositions and optical lenses prepared from the compounds are also provided.

Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.

Abstract: The present invention is directed to novel spiro-benzo[C]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

Abstract: The invention relates to a process for the preparation of compounds containing at least one —CF2—O— bridge in the molecule, in which a) an acid is added onto at least one ketene dithioketal, b) the resultant bis(alkylthio)carbenium salt is reacted with at least one compound having at least one hydroxyl group in the presence of a base, c) and subsequently, preferably in situ, the resultant dithioorthoester is subjected to oxidative fluorodesulfurisation using a fluorinating agent and an oxidant to give the compound containing at least one —CF2—O— bridge in the molecule.

Abstract: A compound having a formula selected from the group consisting of wherein the substituents are as defined in the specification. The compounds are useful as intermediates in the preparation of compounds of formula (I), which are useful for inhibiting NO synthase and regenerate antioxidants.

Abstract: A process for the manufacture of new crystalline salts of N-[2-(dimethylamino)ethyl]-1,2-dithiolane-3-pentanamide (racemic and chiral forms) is described. Such salts are stable, crystalline and have very good solubility in water. The salts exhibit antioxidant properties. They inhibit collagenase and elastase enzymes. They have excellent anti acne activity in addition tyrosinase inhibition. They are, by themselves and in combination with other known agents, important cosmetic ingredients.

Abstract: Disclosed herein are a gelling agent composed of a functional amino acid compound having a tetrathiafulvalenyl group, and a production method of a gelling agent, comprising reacting a tetrathiafulvalene derivative with an amino acid derivative in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-(N,N-dimethylamino)pyridine to obtain a functional amino acid compound having a tetrathiafulvalenyl group.

Abstract: Thienothiophenes compositions comprising a C3-8 secondary or tertiary alkyl group are disclosed. The thienothiophenes may be represented by the formula: where R is C3-8 secondary or tertiary alkyl, e.g., isopropyl, tert-butyl, tert-pentyl, isopentyl, and 2-ethylhexyl, X and X? are independently selected from the group consisting of H, halogen atoms (e.g., F, Cl, Br, and I), MgCl, MgBr, Mgl, Sn(R?)3, (where R? is C1-6 alkyl or —OC1-6 alkyl), boronic acid, boronic ester, —CH?CHR? (where R? is H or C1-6 alkyl), —OC1-6 alkyl, —COOC1-6 alkyl, —S—COR??, —COR?? (where R?? is H or C1-6 alkyl), —C?CH, and polymerizable aromatic rings such as phenyl, naphthalene, pyrrole, dithiophene, thienothiophene, thiophene and so forth.

Abstract: Compositions and methods for using these compositions to produce high yields of thionated compounds are provided.

Abstract: A compound capable of giving optical materials that may be high in both refractive index and Abbe's number and may be excellent in heat resistance and transparency, and a process that may produce the same with good efficiency are disclosed. The compound may be a cyclic disulfide compound including a structure represented by the following general formula (1) or (2) and having a sulfur content of from 50 to 85% by weight: wherein X represents a chain having carbon and/or sulfur as a skeleton, inclusive of cyclic ones; and the number of elements constituting X is from 1 to 4.

Abstract: Compounds of the formulae wherein the substituents are as defined in the specification useful for inhibiting NO synthase and regenerate antioxidants.

Abstract: The present invention provides novel compounds having scavenging and anti-ROS properties and pharmaceutical composition comprising these compounds for treatment of conditions associated with oxidative stress or free radical injury. The compounds of the invention are of general formula (I).

Abstract: The present invention provides an acrylic ester compound represented by formula (1), a polymerizable composition containing the acrylic ester compound, and a cured product and an optical component obtained by polymerizing the polymerizable composition: (wherein “a” is an integer of 0 to 4; R1 is a directly bonded single bond, an alkylene group, an aralkylene group or arylene group which may have a substituent, or a —Y3—S—R4—S—Y4— group (R4 is an alkylene group, an aralkylene group or an arylene group; and Y3 and Y4 are each an alkylene group); R2 and R3 are each a hydrogen atom or an alkyl group; X1 and X2 are each an oxygen atom or a sulfur atom; and Y1 and Y2 are each an alkylene group which may contain an oxygen atom or a sulfur atom).

Abstract: The invention relates to a process for the preparation of compounds having at least one —CF2O— bridge in the molecule, which comprises initially reacting a bis(alkylthio)carbenium salt with a compound containing at least one hydroxyl group in the presence of a base followed by oxidative fluorination, preferably in situ, with a fluorinating agent and an oxidizing agent to form the compound having at least one —CF2O— bridge in the molecule.

Abstract: The compound represented by the general formula (I): wherein each of R1 to R12 and RA1 to RA6 represents a hydrogen atom or a substituent group, and adjacent groups of R1 to R11 and RA1 to RA6 may be bonded to each other to form a ring. The light-emitting device of the present invention comprises a pair of electrodes and one or more organic layers disposed therebetween, at least one of the organic layers comprising the above compound.

Abstract: Process for the synthesis of racemic thiotic acid comprising the following stages: a) reaction of the alkyl ester of 6,8-di-halo-octanoic acid in an organic solvent with an aqueous solution of alkali disulfide in presence of a compound for phase transfer catalysis selected from the group consisting of quaternary ammonium or phosphonium salts having the following general formula: where: A is nitrogen of phosphorus, X is selected from the group consisting of Cl, Br, I, HSO4, and H2PO4 and the substitutents R1, R2, R3 and R4 are selection from the group consisting of linear or branched alkyl radicals having one to twenty carbon atoms (C1-C20), said substituents being identical or different one from the other, or only one of said substituents is selected from the group consisting of arylalkyl radicals having the following formula —(CH2)nC6H5 in which n=1-16; b) followed by the hydrolysis of the ester of racemic thiotic acid.

Abstract: The invention concerns novel lipoic acid derivatives, which have an inhibiting action with respect to NO-synthase enzymes producing nitrogen monoxide NO and/or are agents enabling the regeneration of antioxidants or entities trapping reactive oxygen species (ROS) and intervening in a more general manner in the redox status of thiol groups. The invention also concerns methods for preparing them, pharmaceutical compositions containing them and their use for therapeutic purposes, particularly their use as NO-synthase inhibitors and/or as agents acting more generally in the redox status of thiol groups.

Abstract: Disclosed are methods for treating obstructive and ischemic bladder diseases which include administering a compound which includes a cyclic or acyclic disulfide covalently bonded to a lipid-soluble antioxidant or which include administering a reduced sulfhydryl derivative thereof. Also disclosed are compounds that include a benzopyran moiety which is directly or indirectly covalently bonded to a cyclic or acyclic disulfide, as well as reduced sulfhydryl derivatives of such compounds. Methods for making such compounds and reduced sulfhydryl derivatives using tocopherol and lipoic acid starting materials are also disclosed, as are methods for inhibiting oxidative and/or free radical damage in a subject's cells, nerve membranes, sarcoplasmic reticula, mitochondrial membranes, and/or muscle plasma membranes and methods for treating and/or preventing obstructive and ischemic bladder diseases, conditions involving hypoxia, ischemia, and/or reoxygenation injury.

Abstract: This invention is directed to lipoxin A4 analogs of the following formula (I) and (II): 1

Abstract: The invention relates to reactive thienothiophenes, their use as semiconductors or charge transport materials, in optical, electrooptical or electronic devices like for example organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the reactive thienothiophenes.

Abstract: A sulfur-containing unsaturated carboxylate compound comprising a sulfur-containing substituent and at least two &agr;,&bgr;-unsaturated carboxylic acid residues, which are each attached to a secondary or tertiary carbon atom via an oxygen atom; a polymerizable composition comprising the sulfur-containing unsaturated carboxylate compound; a cured product prepared by polymerizing the polymerizable composition; an optical component consisting of the cured product; and novel intermediate compounds for preparation of the above carboxylate.

Abstract: A compound is provided having the formula I: wherein the variables are defined in the specification. Methods of making the compounds, compositions including the compounds and methods of treatment of conditions involving reactive oxygen species are also provided.

Abstract: A new method for producing unsymmetrically substituted fluorenyl compounds, one step of which is the preparation of 2,7-disubstituted fluoren-9-one derivatives via the nucleophilic substitution of a compound of the formula D wherein A′ is selected from the group consisting of —Br, —Cl, —F, —NO2, and —CN; A is selected from the group consisting of —NO2, —CN, —CO2R, —C(O)R, —SO2R, —SO2RF, —C(CN)═C(CN)2 and —CH═C(CN)2; RF is —CpF2p+1, p=from about 0 to about 10; R is an straight, branched or cyclic aliphatic alkyl group having about 1 to 10 carbon atoms, or an aromatic group such as phenyl or naphthyl; and is a carbonyl or a protected carbonyl such as a ketal or thio-ketal such as wherein R′ is —CrH2r+1; R″ is —(CH2)r—; and r is independently 2 or 3, with a nucleophilic reagent in the presence of an aprotic solvent

Abstract: The present invention describes methods for synthesizing novel dithiolane derivatives, ligands with high affinity for the nuclear hormone receptors, peroxisome proliferator-activated receptor-&ggr; (PPAR&ggr;) and/or PPAR&agr;. Methods for using these compounds in the treatment of endocrine, skin, cardiovascular, immunological, neurological, neuropsychiatric, neoplastic and chronic viral diseases of various organs, including the eye are described. Methods of treating proliferative and inflammatory diseases, degenerative diseases, and age-related dysregulations, caused by an hereditary (genetic) condition or an environmental insult are also provided.

Abstract: A compound is provided having the formula I: 1

Abstract: Disclosed are novel sulfenate esters and thiosulfinate esters that induce the expression of metabolic enzymes, particularly Phase II enzymes such as glutathione-s-transferase, DT-diaphorase and Ferritin H when administered to a subject. Also disclosed, such compounds are effective to displace a zinc ion from retroviral zinc finger nucleocapsid proteins effective to inhibit HIV replication. The present invention is further directed to novel methods of making these compounds, and any compounds produced by the process of making these novel compounds.

Abstract: A compound is provided having the formula I: as defined in the specification. Methods of making the compounds, compositions including the compounds and methods of treatment of conditions involving reactive oxygen species are also provided.

Abstract: The present invention is directed to pharmaceutical compositions including a saturated 1,2-dithiaheterocyclic compound having antiviral activity. The present invention also provides a kit containing the pharmaceutical composition and methods of treating or preventing viral disease using the composition, as well as methods for inactivating retrovirus in a body fluid.

Abstract: Polymeric compositions well suited for conversion into electroconductive shaped articles, e.g., films, comprise at least one convertible polymer (Pm) and at least one amphiphilic organic compound (B) which comprises a charge transfer complex or a radical ion salt having the formula (I): D.sub.d A.sub.a Z.sub.z, in which D is an electron donor; A is an electron acceptor; Z is a doping agent which itself can be a non-amphiphilic electron donor or electron acceptor, with the proviso that at least one of D and A is amphiphilic and contains at least one saturated or unsaturated hydrocarbon substituent having at least 10 carbon atoms; d is a number equal to or greater than 0; a is a number equal to or greater than 0; and z is a number equal to or greater than 0, with the further proviso that at least one of the symbols d and a is a number greater than 0.

Abstract: Polymeric compositions well suited for conversion into electroconductive shaped articles, e.g., films, comprise at least one convertible polymer (Pm) and at least one amphiphilic organic compound (B) which comprises a charge transfer complex or a radical ion salt having the formula (I): D.sub.d A.sub.a Z.sub.z, in which D is an electron donor; A is an electron acceptor; Z is a doping agent which itself can be a non-amphiphilic electron donor or electron acceptor, with the proviso that at least one of D and A is amphiphilic and contains at least one saturated or unsaturated hydrocarbon substituent having at least 10 carbon atoms; d is a number equal to or greater than 0; a is a number equal to or greater than 0; and z is a number equal to or greater than 0, with the further proviso that at least one of the symbols d and a is a number greater than 0.

Abstract: Nonlinear optical compounds which contain a heteroaromatic ring and may further comprise a tricyanovinyl group attached to the heteroaromatic ring.